^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | trastuzumab rezetecan (SHR-A1811) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study
Published date:
10/16/2023
Excerpt:
SHR-A1811 had favorable antitumor activity and acceptable safety profile in heavily pretreated HER2-expressing/mutated advanced non-breast STs, including BTC, UC, GC/GEJA, and CRC.
Trial ID:
